FDA approves J&J`s combination therapy for a type of lung cancer
GSK`s cancer drug combination meets primary goal in late-stage trial
he ongoing shortage of carboplatin and cisplatin across healthcare systems in the United States calls the current reliance on overseas manufacturing of these vital therapies into question, according to Daniel P. Petrylak, MD, who added that shifting the production of platinum-based chemotherapies back to the United States may serve to prevent future shortages.
At least two small biotechs have halted clinical trials due to shortages of cisplatin and carboplatin amid ongoing supply issues for the chemotherapies commonly used in cancer care.
FDA allows more imports of key cancer med from China`s Qilu
Debiopharm has dosed the first patient in a Phase I clinical trial of Debio 0123 combined with carboplatin and etoposide to treat recurrent or progressive small cell lung cancer (SCLC) in patients following a standard platinum-based chemotherapy.
JINAN, China, Dec. 4, 2022 /PRNewswire/ -- Qilu Pharmaceutical, one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures, and distributes both finished formulations and Active Pharmaceutical Ingredients, announced that the results of the phase II study evaluating QL1604 plus chemotherapy as first-line treatment for patients with recurrent or metastatic (R/M) cervical cancer were released on 4 December 2022 in oral presentation (Proffered Paper, 179O) at the European Society for Medical Oncology (ESMO) Asia Congress 2022.
GSK plc (LSE/NYSE: GSK) today announced positive headline results from the planned interim analysis of Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by Jemperli compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent endometrial cancer. The trial met its primary endpoint of investigator-assessed progression-free survival (PFS). It showed a statistically significant and clinically meaningful benefit in the prespecified mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) patient subgroup and in the overall population. A clinically relevant benefit in PFS was also observed in the mismatch repair proficient (MMRp)/microsatellite stable (MSS) patient subgroup.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA, Merck’s anti-PD-1 therapy, plus chemotherapy continued to demonstrate a survival benefit and durable responses in two five-year exploratory analyses of pivotal Phase 3 studies as first-line treatment for metastatic non-small cell lung cancer (NSCLC):